𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of combinations of difluoromethylornithine (DFMO) and 9[(1,3-dihydroxy-2-propoxy) methyl]guanine (DHPG) on human cytomegalovirus

✍ Scribed by Joanne Rush; John Mills

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
458 KB
Volume
21
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Both the nucleoside analog 9[(1,3-dihydroxy-2-propoxy)methyl]guanine (ganciclovir; DHPG) and the polyamine synthesis inhibitor difluoromethylornithine (DFMO) have been reported to inhibit replication of cytomegalovirus (CMV) in vitro. In these studies, DHPG inhibited human CMV replication at concentrations of 0.1 microM or greater, while DFMO was active (and then only inconsistently) at 5 mM or greater. (DFMO was added to cells 3 days before virus to maximize polyamine depletion.) However, DHPG combined with DFMO synergistically inhibited the replication of CMV strain AD169 and one wild-type CMV strain in human foreskin fibroblasts; the effect was evident on both virus yield and plaque formation. The synergistic effect of these two drugs on CMV replication could potentially be exploited clinically to limit drug toxicity or increase efficacy.

πŸ“œ SIMILAR VOLUMES

Electrochemistry of purine derivatives 1
Electrochemistry of purine derivatives 1: Direct determination for the antiviral drug 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine by anodic differential pulse voltammetry
✍ G. C. Visor; S. E. Jackson; R. A. Kenley; G. C. Lee πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 462 KB

Differential pulse voltammetry at a stationary glassy carbon electrode was used for the sensitive and selective analysis of a potent new antiviral analogue of 2-deoxyguanosine in a pharmaceutical formulation. In the electrochemical method for analysis of 9-[l ,(Sdihydroxy-2propoxy)methyl] guanine (I

Efficacy of (S)-1-(3-hydroxy-2-phosphony
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice
✍ Johan Neyts; Jan Balzarini; Lieve Naesens; Erik de Clercq πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 540 KB

## Abstract Mice with severe combined immunodeficiency (SCID) inoculated intraperitoneally with murine cytornegalovirus (MCMV) develop a wasting syndrome at 3–4 days and die at 6–9 days after the infection. 9‐(1,3‐Dihydroxy‐2‐propoxyrnethyl)guanine (DHPG, ganciclovir) and (__S__)‐1‐(3‐hydroxy‐2‐pho